4.7 Review

Pilots flying with insulin-treated diabetes

期刊

DIABETES OBESITY & METABOLISM
卷 23, 期 7, 页码 1439-1444

出版社

WILEY
DOI: 10.1111/dom.14375

关键词

clinical physiology; insulin therapy

向作者/读者索取更多资源

In the past, people with diabetes treated with insulin have often been banned from safety-critical occupations due to fear of incapacitation from hypoglycemia. However, recent advances in insulin therapies and monitoring techniques have challenged these stereotypes. The aviation sector has paved the way for allowing pilots to fly while on insulin, and more countries are changing their minds due to increasing evidence of safety.
People with diabetes treated with insulin have often faced blanket bans from safety-critical occupations, largely because of fear of incapacitation due to hypoglycaemia. Recent advances in insulin therapies, modes of administration, monitoring, and noninvasive monitoring techniques have allowed stereotypical views to be challenged. The aviation sector has led the way, in allowing pilots to fly while on insulin. Recently, countries that have traditionally been opposed to this have changed their minds, largely due to the increasing evidence of safety. The purpose of this review was to gather all available information to update clinicans. The physiology and pathophysiology underpinning glucose regulation and the management of diabetes in the air allowing certain insulin-treated pilots to fly are discussed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Letter Endocrinology & Metabolism

Response to Comment on Russell-Jones et al. Diabetes Care 2017;40:943-950. Comment on Bowering et al. Diabetes Care 2017;40:951-957

Bruce W. Bode, Keith Bowering, David Russell-Jones

DIABETES CARE (2018)

Article Endocrinology & Metabolism

Take Control: A randomized trial evaluating the efficacy and safety of self- versus physician-managed titration of insulin glargine 300 U/mL in patients with uncontrolled type 2 diabetes

David Russell-Jones, Arnaud Dauchy, Elias Delgado, George Dimitriadis, Hans A. Frandsen, Luiza Popescu, Bernd Schultes, Krzysztof Strojek, Mireille Bonnemaire, Aude Roborel de Climens, Melanie Davies

DIABETES OBESITY & METABOLISM (2019)

Article Endocrinology & Metabolism

Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial

Melanie J. Davies, David Russell-Jones, Thomas M. Barber, Fernando J. Lavalle-Gonzalez, Gagik R. Galstyan, Dalong Zhu, Mike Baxter, Cecile Dessapt-Baradez, Rory J. McCrimmon

DIABETES OBESITY & METABOLISM (2019)

Editorial Material Endocrinology & Metabolism

USA joins Canada, UK, Ireland and Austria in allowing people with insulin-treated diabetes to fly commercial aircraft

D. L. Russell-Jones, B. M. Frier, K. M. Shaw

DIABETIC MEDICINE (2020)

Review Endocrinology & Metabolism

100 years of physiology, discrimination and wonder

David Russell-Jones, Roselle Herring

Summary: Research spanning over 100 years has delved into the role of insulin in glucose, protein, and free fatty acid metabolism. By exploring evolution and changes in management, the impact on diabetes care is better understood. The article highlights the discrimination faced and recent advances to empower and counteract it.

DIABETIC MEDICINE (2021)

Article Endocrinology & Metabolism

Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial

Melanie J. Davies, Julio Rosenstock, Amar Ali, David Russell-Jones, Elisabeth Souhami, Karen Palmer, Chen Ji, Elisabeth Niemoeller, Neil Skolnik

Summary: The study demonstrated that in adults with type 2 diabetes inadequately controlled on two oral antidiabetes drugs, iGlarLixi provided better glycemic control compared to iGlar or Lixi, without increasing the risk of hypoglycemia.

DIABETES OBESITY & METABOLISM (2022)

Review Endocrinology & Metabolism

Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes

Athena Philis-Tsimikas, Harpreet S. Bajaj, Kamilla Begtrup, Roman Cailleteau, Amoolya Gowda, Ildiko Lingvay, Chantal Mathieu, David Russell-Jones, Julio Rosenstock

Summary: This article describes the clinical development program ONWARDS phase 3a, which investigates the use of once-weekly basal insulin icodec in the treatment of type 2 and type 1 diabetes. Six trials are being conducted to evaluate the efficacy and safety of icodec, with consideration of different clinical scenarios and comparator treatments.

DIABETES OBESITY & METABOLISM (2023)

Article Endocrinology & Metabolism

Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)

David Russell-Jones, Bruce W. Bode, Christophe De Block, Edward Franek, Simon R. Heller, Chantal Mathieu, Athena Philis-Tsimikas, Ludger Rose, Vincent C. Woo, Anne Birk Osterskov, Tina Graungaard, Richard M. Bergenstal

DIABETES CARE (2017)

暂无数据